July 23, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis."...





Based on the known action of tiludronate, hypocalcemia is a potential consequence of SKELID (tiludronate) overdose. In one patient with hypercalcemia of malignancy, intravenous administration of high doses of SKELID (tiludronate) (800 mg/day total dose, 6 mg/kg/day for 2 days) was associated with acute renal failure and death.

No specific information is available on the treatment of overdose with SKELID (tiludronate) . Dialysis would not be beneficial. Standard medical practices may be used to manage renal insufficiency or hypocalcemia, if signs of these develop.


SKELID (tiludronate) is contraindicated in individuals with known hypersensitivity to any component of this product.

Inability to stand or sit upright for at least 30 minutes.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 4/14/2010


Skelid - User Reviews

Skelid User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Skelid sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Healthy Bones

Get tips and advances in treatment.